GSK Pharma Q2 Review: Temporary Hiccups Lead To Muted Show On A YoY Basis

GlaxoSmithKline Pharmaceuticals Ltd. reported lower-than-expected revenue for the quarter, but Ebitda/PAT were slightly higher than expectations, as controlled costs resulted in improved profitability.

After a healthy pick-up in YoY revenue growth in FY24/FY25, GSK Pharma achieved a revenue decline on a YoY basis in Q2 FY26/H1 FY26. Certain one-time events like the GST transition and the fire incident at GSK Pharma’s contract manufacturing facility contributed to the decline.

Q2 FY26 Performance Review

GSK Pharma’s revenue for Q2 FY26 stood at Rs. 872 crore, a decline of 4.5% YoY. The decline was primarily due to the one-time events mentioned earlier. However, the company’s Ebitda for the quarter was Rs. 234 crore, up 14.5% YoY, driven by controlled costs and improved profitability.

The company’s PAT for the quarter was Rs. 144 crore, up 15.5% YoY. The improvement in profitability was driven by the company’s focus on cost control and operational efficiency.

Motilal Oswal Maintains Neutral Stance

Motilal Oswal has maintained a neutral stance on GSK Pharma, citing the company’s temporary hiccups and muted show on a YoY basis. The brokerage firm has set a target price of Rs. 1,450 for the stock.

Motilal Oswal believes that GSK Pharma’s performance will improve in the coming quarters, driven by the company’s strong product portfolio and improving profitability. However, the brokerage firm has cautioned that the company’s revenue growth may be impacted by the one-time events mentioned earlier.

Indian Pharmaceutical Sector Overview

The Indian pharmaceutical sector has been performing well in recent years, driven by the country’s growing demand for healthcare services and the government’s initiatives to promote the sector.

According to a report by Indian Pharmaceutical Sector, the sector is expected to grow at a CAGR of 10-12% in the next 5 years, driven by the increasing demand for generic drugs and the growing presence of Indian pharmaceutical companies in the global market.

Investment Opportunities in the Pharmaceutical Sector

The pharmaceutical sector offers several investment opportunities for investors, including pharmaceutical stocks, pharmaceutical mutual funds, and pharmaceutical ETFs.

Investors can also consider investing in healthcare sector stocks, which include hospitals, diagnostic centers, and medical equipment manufacturers.

Conclusion

GSK Pharma’s Q2 FY26 performance was impacted by temporary hiccups, but the company’s controlled costs and improved profitability are positive signs for investors. Motilal Oswal’s neutral stance on the stock is also a positive sign, as it indicates that the brokerage firm expects the company’s performance to improve in the coming quarters.

Investors can consider investing in GSK Pharma and other pharmaceutical stocks, but it is essential to do thorough research and analysis before making any investment decisions. It is also essential to consider the overall performance of the Indian stock market and the global economic trends before making any investment decisions.